The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic, predictive, and surrogate value of HER2 extracellular domain (ECD) for progression-free survival (PFS) in advanced breast cancer treated with lapatinib (lap): A meta-analysis.
Chee Lee
Other Remuneration - GlaxoSmithKline
Lucy Davies
No relevant relationships to disclose
Ian Marschner
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Sally Lord
No relevant relationships to disclose
Angelo Di Leo
Consultant or Advisory Role - Roche
Honoraria - Roche
Stephen R. D. Johnston
No relevant relationships to disclose
Charles E. Geyer
No relevant relationships to disclose
David A. Cameron
Consultant or Advisory Role - GlaxoSmithKline; Roche
Honoraria - GlaxoSmithKline; Roche
Michael F. Press
Consultant or Advisory Role - GlaxoSmithKline; Merrimack Pharmaceuticals
Honoraria - GlaxoSmithKline
Catherine Elizabeth Ellis
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Sherene Loi
Employment or Leadership Position - Peter MacCallum Cancer Centre
John Simes
No relevant relationships to disclose
Paul De Souza
Consultant or Advisory Role - GlaxoSmithKline